FEED on OTC

ENvue Medical, Inc.

American orthopedic company that raised $13.8 million in 2023 (SEC Form D). Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with CollPlant Biotechnologies Ltd, NutriBand Inc. or Anteris Technologies Global Corp., or pick any stock.

  • TickerFEED on OTC1
  • IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies1
  • HeadquartersTyler, Texas1
  • Incorporated inDE2
  • Business address969 Pruitt Ave,, Tyler, Tx 775692
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Merger, the “Merger”), with Second Merger Sub being the surviving entity of the Second Merger (“Surviving Entity”).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

6.0%Gross margin4
-896.6%Operating margin4
-712.3%Net margin4
-0.2%Revenue growth, 20254
-54.3%Return on equity4
-$9.4MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Nano Vibronix brought in 73% of the revenue ENvue Medical, Inc. broke down this way in fiscal 2025.

  1. Nano Vibronix$1.9M473%down 27% from 2024
  2. ENvue$696.0K427%
Business segments by year
Business segments20242025
Nano Vibronix$2.6M$1.9M
ENvue$696.0K

Regions

United States brought in 98% of the revenue ENvue Medical, Inc. broke down this way in fiscal 2025.

  1. United States$2.5M498%up 2% from 2024
  2. Australia/New Zealand$20.0K41%down 51% from 2024
  3. Other Country$15.0K41%down 70% from 2024
  4. Europe$8.0K40%down 53% from 2024
Regions by year
Regions20242025
United States$2.5M$2.5M
Australia/New Zealand$41.0K$20.0K
Other Country$50.0K$15.0K
Europe$17.0K$8.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue54¢$2.4M
  • Research and development39¢$1.8M
  • Income tax7¢$307.0K

Out of $2.6M in revenue.4 The company lost money this year.

Financial statements

Revenue567894$2.6M in 2025+382% since 2019
0$1.0M$2.0M$3.0M2019: $530.0K$530.0K20192020: $623.0K$623.0K2020+18%2021: $1.7M$1.7M2021+172%2022: $752.0K$752.0K2022−56%2023: $2.3M$2.3M2023+204%2024: $2.6M$2.6M2024+12%2025: $2.6M$2.6M2025−0%
Gross profit567894$153.0K in 2025−46% since 2019
0$500.0K$1.0M$1.5M$2.0M2019: $281.0K$281.0K20192020: $214.0K$214.0K2020−24%2021: $770.0K$770.0K2021+260%2022: $167.0K$167.0K2022−78%2023: $1.5M$1.5M2023+820%2024: $1.5M$1.5M2024−2%2025: $153.0K$153.0K2025−90%
Operating income567894-$22.9M in 2025+344% since 2019
-$30.0M-$20.0M-$10.0M02019: -$5.2M-$5.2M20192020: -$4.7M-$4.7M2020−8%2021: -$5.7M-$5.7M2021+20%2022: -$5.0M-$5.0M2022−12%2023: -$3.4M-$3.4M2023−31%2024: -$3.6M-$3.6M2024+4%2025: -$22.9M-$22.9M2025+539%
Net income567894-$18.2M in 2025+214% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$5.8M-$5.8M20192020: -$4.3M-$4.3M2020−25%2021: -$14.3M-$14.3M2021+230%2022: -$5.4M-$5.4M2022−62%2023: -$3.7M-$3.7M2023−32%2024: -$3.7M-$3.7M2024−0%2025: -$18.2M-$18.2M2025+391%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenues$2.6M$2.6M
Cost of revenues$2.4M$1.1M
Gross profit$153.0K$1.5M
Research and development$1.8M$909.0K
Selling and marketing$2.5M$720.0K
General and administrative$7.6M$3.5M
Impairment of goodwill and long-lived assets$11.2M
Total operating expenses$23.0M$5.1M
Loss from operations-$22.9M-$3.6M
Financial income (expense), net$4.4M-$104.0K
Loss before taxes on income-$18.5M-$3.7M
Income tax (expense) benefit$307.0K-$19.0K
Net loss-$18.2M-$3.7M
Dividend on Series X Preferred Stock-$1.7M
Dividend on Series H Preferred Stock-$396.0K
Deemed dividend for down round feature on Series H Preferred Stock-$399.0K
Deemed contribution on repurchase of Preferred Series X$90.0K
Deemed contribution on modification of Preferred Series X$3.8M
Net loss available to common stockholders-$16.8M-$3.7M
Basic net loss available for holders of common stock-$26.69-$137.30
Diluted net loss available for holders of common stock-$26.69-$137.30
Weighted average common stock outstanding, basic628.5K shares27.0K shares
Weighted average common stock outstanding, diluted628.5K shares27.0K shares
Change in foreign currency translation adjustments-$13.0K
Total Comprehensive loss-$18.2M-$3.7M

Compare ENvue Medical, Inc. with another company

Leadership

Who has led ENvue Medical, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Stephen Russell Brown2015–2026
  2. Nicole M. Fernandez-Mcgovern2026–now
20202025
Board members and other officers (16)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Executive Officer and DirectorBrian Murphy named Jun 29, 2022 to Sep 13, 202328
  • DirectorMika R. Thomas named Jun 29, 202229

Former names

  • NanoVibronix, Inc.Apr 30, 2014 to Dec 12, 20252
  • Nano Vibronix, Inc.Dec 6, 2011 to Mar 25, 20142
  • Nano Vibronix IncMay 5, 2005 to May 5, 20052

Filings

249 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 86 major events, 50 insider forms, 10 large holders, 2 private raises, 78 other. The latest 20:

  1. Oct 14, 20268-K EDGAR
  2. Sep 3, 2026EFFECT EDGAR
  3. Aug 31, 20268-K EDGAR
  4. Aug 17, 202610-Q EDGAR
  5. Aug 14, 2026NT 10-Q EDGAR
  6. Aug 14, 20268-K EDGAR
  7. Aug 12, 20268-K EDGAR
  8. Aug 10, 2026S-3 EDGAR
  9. Jul 24, 2026DEF 14A EDGAR
  10. Jul 14, 2026PRE 14A EDGAR
  11. Jul 14, 20268-K EDGAR
  12. Jul 10, 20268-K EDGAR
  13. Jun 22, 2026SCHEDULE 13D/A EDGAR
  14. Jun 22, 20264 PRIMARY DOCUMENT EDGAR
  15. May 28, 2026EFFECT EDGAR
  16. May 28, 2026424B3 EDGAR
  17. May 26, 2026CORRESP EDGAR
  18. May 26, 2026UPLOAD EDGAR
  19. May 18, 2026S-3 EDGAR
  20. May 18, 202610-Q EDGAR

The 249 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 5 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 22, 2026Glibert Christian MichaelSale210,000$0.69$144.9KForm 4
Feb 2, 2026BANK OF AMERICA CORP /DE/10% ownerSale2,918$3.05$8.9KForm 4
Jan 14, 2026Glibert Christian MichaelBuy240,000$2.67$640.8KForm 4
Jan 5, 2023MIKA THOMASDirectorBuy50,000$0.25$12.5KForm 4
Jun 15, 2022FASHEK CHRISTOPHER MDirectorBuy40,000$0.60$24.0KForm 4
Jun 14, 2022BROWN STEPHEN RUSSELLChief Financial OfficerBuy4,000$0.57$2.3KForm 4
Jun 1, 2022Cassirer AuroraDirectorBuy2,000$0.69$1.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 30, 2023Raised $13.5 million in a private offering of equity Form D: 1 investor so far Form D
  2. Jun 14, 2022Raised $250,000 in a private offering of securities Form D: 1 investor so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33